Outcomes of platelet-rich plasma for plantar fasciopathy: a best-evidence synthesis

Background Plantar fasciopathy (PF) is a very common disease, affecting about 1/10 people in their lifetime. Platelet-rich plasma (PRP) had been demonstrated to be useful in achieving helpful effects for plantar fasciopathy. The purpose of this study was to compare the pain and functional outcomes b...

Full description

Saved in:
Bibliographic Details
Published in:Journal of orthopaedic surgery and research 2020-09, Vol.15 (1), p.1-432, Article 432
Main Authors: Yu, Tao, Xia, Jiang, Li, Bing, Zhou, Haichao, Yang, Yunfeng, Yu, Guangrong
Format: Article
Language:English
Subjects:
Bias
Clinical trials
Comparative analysis
Corticosteroid
Corticosteroids
Fasciopathy
Glucocorticoids
Orthopedics
Pain
Plantar fasciitis
Plasma
Platelet-rich plasma
Platelets
Sensitivity analysis
Systematic Review
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Plantar fasciopathy (PF) is a very common disease, affecting about 1/10 people in their lifetime. Platelet-rich plasma (PRP) had been demonstrated to be useful in achieving helpful effects for plantar fasciopathy. The purpose of this study was to compare the pain and functional outcomes between PRP and corticosteroid (CS) or placebo for plantar fasciopathy through meta-analysis and provide the best evidence. Methods Literature was searched systematically to explore related studies that were published in Cochrane Library, PubMed, Embase, Medline, SpringerLink, OVID, and ClinicalTrials.gov. Articles regarding comparative research about the outcomes of PRP therapy and CS or placebo injection were selected. Data of pain and functional outcomes was extracted and imported into Reviewer Manager 5.3 to analyze. Results Thirteen RCTs were included and analyzed. Analysis results showed significant superiority of PRP in outcome scores when compared with CS (VAS: MD = - 0.85, P < 0.0001, I.sup.2 = 85%; AOFAS: MD = 10.05, P < 0.0001, I.sup.2 = 85%), whereas there is no statistical difference in well-designed double-blind trials (VAS: MD = 0.15, P = 0.72, I.sup.2 = 1%; AOFAS: MD = 2.71, P = 0.17, I.sup.2 = 0%). In the comparison of the PRP and the placebo, the pooled mean difference was - 3.76 (P < 0.0001, 95% CI = - 4.34 to - 3.18). Conclusions No superiority of PRP had been found in well-designed double-blind studies, whereas it is implied that the outcomes of PRP are better than placebo based on available evidence. Keywords: Platelet-rich plasma, Corticosteroid, Fasciopathy, Therapy
ISSN:1749-799X
1749-799X
DOI:10.1186/s13018-020-01783-7